Wall Street analysts expect Steris (STE) to post quarterly earnings of $2.11 per share in its upcoming report, which indicates a year-over-year increase of 3.9%. Revenues are expected to be $1.34 billion, down 0.4% from the year-ago quarter.Over the last 30 days, there has been a downward revision of 1.3% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.Ah ...

DUBLIN, IRELAND, Oct. 30, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.57 per share. The dividend is payable on December 19, 2024, to shareholders of record at the close of business on November 19, 2024.   Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com. STERIS is a leading global provider of products and service ...

DUBLIN, IRELAND, Oct. 23, 2024 (GLOBE NEWSWIRE) --  STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2025 second quarter financial results at 9:00 a.m. ET on November 7, 2024. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.   A press release detailing financial results will ...

STERIS plc (STE) is expected to release second-quarter fiscal 2025 results shortly. In the last reported quarter, the company posted adjusted earnings per share (EPS) of $2.03, which beat the Zacks Consensus Estimate by 1%. STE beat on earnings in three of the trailing four quarters and missed the same once, delivering an average surprise of 0.58%. Find the latest EPS estimates and surprises on Zacks Earnings Calendar. STE's Q2 Estimates The Zacks Consensus Estimate for revenues is pegged at $1.34 billion, ...

A month has gone by since the last earnings report for Steris (STE) . Shares have added about 3% in that time frame, underperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Steris due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. STERIS Q1 Earnings Beat Estimates, Operating Margin Falls STERI ...

STERIS plc (STE) rides on the robust performance of its Healthcare business.The company also benefits from the strong rebound prospects for its Applied Sterilization Technologies ("AST") segment. Meanwhile, headwinds such as foreign currency risks and macroeconomic challenges are concerning. Year to date, shares of this Zacks Rank #3 (Hold) company have risen 10.6% compared with the industry's 10% growth and the S&P 500's 18.4% increase. The renowned provider of infection prevention and other procedural pro ...

DUBLIN, IRELAND, Aug. 26, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) ("STERIS" or the "Company") announced today that it will participate in the Morgan Stanley Healthcare Conference in New York City on Wednesday, September 4, 2024. Dan Carestio, President and CEO of STERIS will present at 1:50 p.m. Eastern Time. A simultaneous webcast and replay of the Company's presentation will be available on STERIS's investor relations website at www.steris-ir.com. STERIS is a leading global provider of products an ...

I I F ■ F Matteo Colombo Investment update Following my last publication on STERIS plc (NYSE:STE) the stock is +2.5% in the green after backing and filling into congestion. The company's Q1 FY'25 numbers gleaned several insights that provide a comprehensive view into what to expect for the remainder of the financial year. That report, titled "Remains on track for strong fiscal 24", outlined several bullish factors in the debate, including: STE staged an upside move off lows in early '23, where I advocated b ...

Have you evaluated the performance of Steris' (STE) international operations for the quarter ending June 2024? Given the extensive global presence of this medical products maker, analyzing the patterns in international revenues is crucial for understanding its financial strength and potential for growth. The global economy today is deeply interlinked, making a company's engagement with international markets a critical factor in determining its financial success and growth path. It has become essential for i ...

Financial Performance - Revenues increased by 8.1% to $1,279.5 million for the three months ended June 30, 2024, compared to $1,183.4 million for the same period in the prior year[86]. - Gross profit percentage remained stable at 44.7% for both the first three months of fiscal 2025 and fiscal 2024[86]. - Income from operations decreased to $185.5 million in the first three months of fiscal 2025 from $197.8 million in the same period of fiscal 2024, primarily due to restructuring expenses[86]. - Cash flows from operations were $303.7 million for the first three months of fiscal 2025, an increase from $281.1 million in the same period of fiscal 2024[86]. - Free cash flow for the first three months of fiscal 2025 was $195.7 million, down from $214.5 million in the same period of fiscal 2024[86]. - Total revenues increased by 8.1% to $1,279.5 million for the three months ended June 30, 2024, compared to $1,183.4 million for the same period in the prior year[90]. - Gross profit for the three months ended June 30, 2024, was $572.4 million, an increase of 8.2% from $529.0 million in the prior year, with a gross profit percentage of 44.7%[91]. - Operating expenses increased by 16.8% to $386.9 million, driven by a 9.5% rise in selling, general, and administrative expenses to $335.6 million[92]. - Total segment operating income increased by 7.4% to $285.4 million for the three months ended June 30, 2024, compared to $265.7 million in 2023[101]. - Net income for the three months ended June 30, 2024, was $107.3 million, reflecting strong operational performance[106]. Debt and Cash Management - The debt-to-total capital ratio improved to 26.7% at June 30, 2024, from 33.7% at March 31, 2024[86]. - The company reported a debt-to-total capital ratio of 26.7% for the three months ended June 30, 2024, down from 32.2% in 2023[102]. - Outstanding borrowings under the Revolving Credit Facility were $231.3 million as of June 30, 2024[103]. - The company intends to use existing cash and cash equivalents for both short-term and long-term capital expenditures, depending on various uncertain factors[103]. Acquisitions and Divestitures - The company completed the acquisition of surgical instrumentation assets from Becton, Dickinson and Company for $539.8 million, which was financed through existing credit facilities[85]. - The company recorded net proceeds of $41.5 million from the sale of its Controlled Environment Certification Services business, with a pre-tax gain of $18.8 million[85]. - The Dental segment was sold for total cash consideration of $787.5 million, with an additional contingent payment of up to $12.5 million based on revenue targets[86]. - The company received proceeds of $809.6 million from the sale of its Dental segment and CECS business during the first three months of fiscal 2025[102]. Segment Performance - Service revenues rose by 9.2% to $623.2 million, while consumable revenues increased by 20.8% to $414.1 million, reflecting growth in the Healthcare and Life Sciences segments[90]. - Healthcare segment revenues increased by 10.1% to $901.2 million for the three months ended June 30, 2024, compared to $818.9 million for the same period in 2023[98]. - AST segment revenues rose by 7.2% to $249.8 million for the three months ended June 30, 2024, compared to $233.1 million in the prior year[98]. - Life Sciences segment revenues decreased by 2.2% to $128.5 million for the three months ended June 30, 2024, down from $131.4 million in the same prior year period[98]. - The Healthcare segment's backlog decreased to $362.0 million as of June 30, 2024, from $491.7 million a year earlier[98]. - The Life Sciences backlog also decreased to $72.2 million as of June 30, 2024, down from $104.9 million in the prior year[98]. Expenses and Taxation - Research and development expenses grew by 3.6% to $25.6 million, focusing on new product development and technological innovations[92]. - The company recorded total pre-tax restructuring expenses of $28.1 million for the three months ended June 30, 2024, related to a targeted restructuring plan[93]. - Interest expense decreased by $2.0 million to $30.4 million, primarily due to a lower principal amount of debt outstanding[94]. - Income tax expense for the three months ended June 30, 2024, was $35.3 million, with an effective income tax rate of 20.1%, down from 21.7% in the prior year[95]. Future Outlook and Risks - The company anticipates improvements in income from operations of approximately $25.0 million per year from the restructuring actions, with benefits expected to materialize in fiscal 2026 and beyond[92]. - STERIS's restructuring plan may not yield expected benefits or be realized on the anticipated timeline, affecting financial results[112]. - The company faces potential risks from public health crises impacting operations, supply chain, and costs[112]. - STERIS's ability to integrate acquired businesses successfully is uncertain, which could lead to increased costs or liabilities[112]. - The company is monitoring the impact of international unrest and economic downturns on demand for its products and services[112]. Legal and Regulatory Matters - The company is involved in various legal proceedings and claims, but does not anticipate a material adverse effect on its financial position or results of operations[110]. - STERIS's quarterly report includes forward-looking statements that may be affected by various factors, including market conditions and regulatory actions[111]. Market Risks - The company is subject to various market risks, including interest rate, currency, and commodity risks, which have not changed materially since March 31, 2024[114]. - STERIS's financial results could be impacted by the availability and price changes of basic raw materials, with long-term supply contracts in place to ensure reliability[114]. - The company has commodity swap contracts to buy 591.8 thousand pounds of nickel, which may help hedge against price fluctuations[114]. - There were no changes in internal control over financial reporting that materially affected the company's reporting during the quarter ended June 30, 2024[115].